VCEL (Vericel) Quality Rank


VCEL Vericel Corp VCEL
81 GF Score
Price $45.07
GF Value $54.29
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Vericel Quality Rank Related Terms

VCEL
81GF Score
Vericel Corp VCEL
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (VCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of $45.07 is trading 17% below its estimated GF Value™ of $54.29. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for VCEL:

  • Quality Rank:
  • GF Value™: $54.29 vs. price of $45.07 (17% below fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the VCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges ATQP:Germany
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
81GF Score

Get the complete analysis for VCEL

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.07
Price
$54.29
GF Value